Skip to main content
Erschienen in: Lung 1/2005

01.02.2005

The Role of Pleural Fluid-Serum Gradient of Tumor Necrosis Factor-α Concentration in Discrimination Between Complicated and Uncomplicated Parapneumonic Effusion

verfasst von: M. Odeh, B. Makhoul, E. Sabo, I. Srugo, A. Oliven

Erschienen in: Lung | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

In a previous preliminary study an excess of tumor necrosis factor-α (TNF) was found in pleural fluid of patients with complicated parapneumonic effusion (CPPE), and its levels in pleural fluid of these patients were shown to be significantly higher than those in patients with uncomplicated parapneumonic effusion (UCPPE). This larger population study was undertaken to investigate, for the first time, the role of pleural fluid-serum gradient of TNF (TNFgradient) in discrimination between UCPPE and CPPE. Using a commercially available high sensitivity ELISA kit, levels of TNF were measured in serum and pleural fluid of 51 patients with UCPPE and 30 patients with nonempyemic CPPE. The mean ± SEM values of serum TNF (TNFserum), pleural fluid TNF (TNFpf), and TNFgradient in the UCPPE group were 6.65 ± 0.48 pg/mL, 10.85 ± 0.74 pg/mL, and 4.2 ± 0.38 pg/mL respectively, and in the CPPE group they were 7.59 ± 0.87 pg/mL, 54.02 ± 5.43 pg/mL, and 46.43 ± 5.34 pg/mL, respectively. While no significant difference was found between the two groups regarding levels of TNFserum (p = 0.31), a highly significant difference between these two groups was found regarding levels of TNFpf and TNFgradient (p < 0.0001 for both variables). A significant correlation was found between levels of TNFserum and levels of TNFpf in the UCPPE group (r = 0.89, p < 0.0001), but not in the CPPE group (r = 0.18, p < 0.33). TNFgradient at an optimal cut-off level of 9.0 pg/mL was found to be a good marker for discrimination between UCPPE and CPPE (sensitivity, 96.7%, specificity, 98%, accuracy, 97.5%, and p < 0.0001). In conclusion, levels of TNFpf but not TNFserum are significantly higher in CPPEs than those in UCPPEs where TNFgradient at an optimal cut-off level of 9.0 pg/mL is a good marker for discrimination between UCPPE and CPPE.
Literatur
1.
Zurück zum Zitat Alkrinawi, S, Chirnick, V 1996Pleural fluid in hospitalized pediatric patientsClin Pediatr (Phila)3559 Alkrinawi, S, Chirnick, V 1996Pleural fluid in hospitalized pediatric patientsClin Pediatr (Phila)3559
2.
Zurück zum Zitat Andrews, NC, Parker, EF, Shaw, RR, Wilson, NJ, Webb, WR 1962Management of nontuberculous empyemaAm Rev Respir Dis85935936 Andrews, NC, Parker, EF, Shaw, RR, Wilson, NJ, Webb, WR 1962Management of nontuberculous empyemaAm Rev Respir Dis85935936
3.
Zurück zum Zitat Baughman, RP, Doers, J, Lower, EE, Buehsbaum, J 1989Isolation of functionally active pleural macrophagesJ Clin Immunol30147151 Baughman, RP, Doers, J, Lower, EE, Buehsbaum, J 1989Isolation of functionally active pleural macrophagesJ Clin Immunol30147151
4.
Zurück zum Zitat Baughman, RP, Lower, EE 1991An inhibitor of tumor necrosis factor found in pleural effusionsJ Lab Clin Med118326331 Baughman, RP, Lower, EE 1991An inhibitor of tumor necrosis factor found in pleural effusionsJ Lab Clin Med118326331
5.
Zurück zum Zitat Bazzoni, F, Cassatella, MA, Laudanna, C, Rossi, F 1991Phagocytosis of opsonized yeast induces tumor necrosis factor-α mRNA accumulation and protein release by human polymorphonuclear leukocytesJ Leukoc Biol50223228 Bazzoni, F, Cassatella, MA, Laudanna, C, Rossi, F 1991Phagocytosis of opsonized yeast induces tumor necrosis factor-α mRNA accumulation and protein release by human polymorphonuclear leukocytesJ Leukoc Biol50223228
6.
Zurück zum Zitat Beutler, B, Cerami, A 1987Cachectin: more than a tumor necrosis factorN Engl J Med316479485 Beutler, B, Cerami, A 1987Cachectin: more than a tumor necrosis factorN Engl J Med316479485
7.
Zurück zum Zitat Beutler, BA 1999The role of tumor necrosis factor in health and diseaseJ Rheumatol261621 Beutler, BA 1999The role of tumor necrosis factor in health and diseaseJ Rheumatol261621
8.
Zurück zum Zitat Broaddus, VC, Herbert, CA, Vitangcol, RV, Hoeffel, JM, Bernstein, MS, Boylan, AM 1992Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyemaAm Rev Respir Dis146825830 Broaddus, VC, Herbert, CA, Vitangcol, RV, Hoeffel, JM, Bernstein, MS, Boylan, AM 1992Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyemaAm Rev Respir Dis146825830
9.
Zurück zum Zitat Cassatella, MA 1995The production of cytokines by polymorphonuclear neutrophilsImmunol Today162126 Cassatella, MA 1995The production of cytokines by polymorphonuclear neutrophilsImmunol Today162126
10.
Zurück zum Zitat Cassatella, MA 1999Neutrophil-derived proteins: selling cytokines by the poundAdv Immunol73369509 Cassatella, MA 1999Neutrophil-derived proteins: selling cytokines by the poundAdv Immunol73369509
11.
Zurück zum Zitat Coker, RK, Laurent, GJ 1998Pulmonary fibrosis: cytokines in the balanceEur Respir J1112181221 Coker, RK, Laurent, GJ 1998Pulmonary fibrosis: cytokines in the balanceEur Respir J1112181221
12.
Zurück zum Zitat Colice, GL, Curtis, A, Deslauriers, J, et al. 2000Medical and surgical treatment of parapneumonic effusions: an evidence-based guidelineChest1811581171 Colice, GL, Curtis, A, Deslauriers, J,  et al. 2000Medical and surgical treatment of parapneumonic effusions: an evidence-based guidelineChest1811581171
13.
Zurück zum Zitat Colotta, F, Re, F, Polentarutti, N, Sozzani, S, Mantovani, A 1992Modulation of granuloeyte survival and programmed cell death by cytokines and bacterial productsBlood8020122020 Colotta, F, Re, F, Polentarutti, N, Sozzani, S, Mantovani, A 1992Modulation of granuloeyte survival and programmed cell death by cytokines and bacterial productsBlood8020122020
14.
Zurück zum Zitat Davies, CWH, Gleeson, FV, Davies, RJO 2003BTS guidelines for the management of pleural infectionThorax58ii18ii28 Davies, CWH, Gleeson, FV, Davies, RJO 2003BTS guidelines for the management of pleural infectionThorax58ii18ii28
15.
Zurück zum Zitat De Pablo, A, Villena, V, Echave-Sustaeta, J, Encuntra, AL 1997Are pleural fluid parameters related to the development of residual pleural thickening in tuberculosis?Chest11212931297 De Pablo, A, Villena, V, Echave-Sustaeta, J, Encuntra, AL 1997Are pleural fluid parameters related to the development of residual pleural thickening in tuberculosis?Chest11212931297
16.
Zurück zum Zitat Doers, J, Baughman, RP, Buchsbaum, J, Lower, EE 1989Tumor necrosis factor production by pleural macrophagesAm Rev Respir Dis139A360 Doers, J, Baughman, RP, Buchsbaum, J, Lower, EE 1989Tumor necrosis factor production by pleural macrophagesAm Rev Respir Dis139A360
17.
Zurück zum Zitat Hamm, H, Light, RW 1997Parapneumonic effusions and empyemaEur Respir J1011501156 Hamm, H, Light, RW 1997Parapneumonic effusions and empyemaEur Respir J1011501156
18.
Zurück zum Zitat Heffner, JE, Brown, LK, Barbieri, C, Deleo, JM 1995Pleural fluid chemical analysis in parapneumonic effusionsAm J Respir Crit CareMed 15117001708 Heffner, JE, Brown, LK, Barbieri, C, Deleo, JM 1995Pleural fluid chemical analysis in parapneumonic effusionsAm J Respir Crit CareMed 15117001708
19.
Zurück zum Zitat Heffner, JE, McDonald, J, Barbieri, C, et al. 1995Management of parapneumonic effusionArch Surg130433438 Heffner, JE, McDonald, J, Barbieri, C,  et al. 1995Management of parapneumonic effusionArch Surg130433438
20.
Zurück zum Zitat Herbein, G, O’Brien, WA 2000Tumor necrosis factor (TNF)-α and TNF receptors in viral pathogenesisProc Soc Exp Biol Med223241257 Herbein, G, O’Brien, WA 2000Tumor necrosis factor (TNF)-α and TNF receptors in viral pathogenesisProc Soc Exp Biol Med223241257
21.
Zurück zum Zitat Hua, C-C, Chang, L-C, Chen, Y-C, Chang, S-C 1999Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusionsChest11612921296 Hua, C-C, Chang, L-C, Chen, Y-C, Chang, S-C 1999Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusionsChest11612921296
22.
Zurück zum Zitat Kroegel, C, Antony, VB 1997Immunobiology of pleural imflammation: potential implications for pathogenesis, diagnosis and therapyEur Respir J11024112418 Kroegel, C, Antony, VB 1997Immunobiology of pleural imflammation: potential implications for pathogenesis, diagnosis and therapyEur Respir J11024112418
23.
Zurück zum Zitat Light, RW, Girard, WM, Jenkinson, SG, George, RB 1980Parapneumonic effusionsAm J Med69507511 Light, RW, Girard, WM, Jenkinson, SG, George, RB 1980Parapneumonic effusionsAm J Med69507511
24.
Zurück zum Zitat Light, RW 1995A new classification of parapneumonic effusions and empyemaChest108299301 Light, RW 1995A new classification of parapneumonic effusions and empyemaChest108299301
25.
Zurück zum Zitat Miyazaki, Y, Araki, K, Vesin, C, et al. 1995Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitisJ Clin Invest96250259 Miyazaki, Y, Araki, K, Vesin, C,  et al. 1995Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitisJ Clin Invest96250259
26.
Zurück zum Zitat O’Brien, DP, Briles, DE, Szalai, AJ, Tu, AH, Sanz, I, Nahm, MN 1999Tumor necrosis factor-alpha receptor I is important for survival from Streptococcus pneumonia infectionsInfect Immun76595601 O’Brien, DP, Briles, DE, Szalai, AJ, Tu, AH, Sanz, I, Nahm, MN 1999Tumor necrosis factor-alpha receptor I is important for survival from Streptococcus pneumonia infectionsInfect Immun76595601
27.
Zurück zum Zitat Odeh, M 1990The role of tumour necrosis factor-α in acquired immunodeficiency syndromeJ Intern Med228549556 Odeh, M 1990The role of tumour necrosis factor-α in acquired immunodeficiency syndromeJ Intern Med228549556
28.
Zurück zum Zitat Odeh, M, Sabo, E, Oliven, A, Srugo, I 1999Role of tumor necrosis factor-α in the differential diagnosis of parapneumonic effusionInt J Infect Dis43841 Odeh, M, Sabo, E, Oliven, A, Srugo, I 1999Role of tumor necrosis factor-α in the differential diagnosis of parapneumonic effusionInt J Infect Dis43841
29.
Zurück zum Zitat Odeh, M 2001The role of tumour necrosis factor-α in the pathogenesis of complicated falciparum malariaCytokine141118 Odeh, M 2001The role of tumour necrosis factor-α in the pathogenesis of complicated falciparum malariaCytokine141118
30.
Zurück zum Zitat Odeh, M, Sabo, E, Srugo, I, Oliven, A 2002Correlation between polymorphonuclear leukocyte counts and levels of tumor necrosis factor-α in pleural fluid of patients with parapneumonic effusionLung180265271 Odeh, M, Sabo, E, Srugo, I, Oliven, A 2002Correlation between polymorphonuclear leukocyte counts and levels of tumor necrosis factor-α in pleural fluid of patients with parapneumonic effusionLung180265271
31.
Zurück zum Zitat Porcel JM, Vazquez P, Vives M, et al. (2003) Pleural space infections: microbiologic and fluid characteristics in 84 patients. Internet J Pulmonary Med 3(1). Available at: http://www.ispub.com/journals/ijpm/archives Porcel JM, Vazquez P, Vives M, et al. (2003) Pleural space infections: microbiologic and fluid characteristics in 84 patients. Internet J Pulmonary Med 3(1). Available at: http://​www.​ispub.​com/​journals/​ijpm/​archives
32.
Zurück zum Zitat Porcel, JM, Vives, M, Esquerda, A 2004Tumor necrosis factor-α in pleural fluid: a marker of complicated parapneumonic effusionsChest125160164 Porcel, JM, Vives, M, Esquerda, A 2004Tumor necrosis factor-α in pleural fluid: a marker of complicated parapneumonic effusionsChest125160164
33.
Zurück zum Zitat Sahn, SA 1993Management of complicated parapneumonic effusionsAm Rev Respir Dis148813817 Sahn, SA 1993Management of complicated parapneumonic effusionsAm Rev Respir Dis148813817
34.
Zurück zum Zitat Taryle, DA, Potts, DE, Sahn, SA 1978The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumoniaChest74170173 Taryle, DA, Potts, DE, Sahn, SA 1978The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumoniaChest74170173
35.
Zurück zum Zitat Tracey, KJ, Vlassara, H, Cerami, A 1989Cachectin: tumour necrosis factorLancetii11221126 Tracey, KJ, Vlassara, H, Cerami, A 1989Cachectin: tumour necrosis factorLancetii11221126
36.
Zurück zum Zitat Tracey, KJ, Cerami, A 1994Tumor necrosis factor: a pleiotropic cytokine and therapeutic targetAnnu Rev Med45491503CrossRefPubMed Tracey, KJ, Cerami, A 1994Tumor necrosis factor: a pleiotropic cytokine and therapeutic targetAnnu Rev Med45491503CrossRefPubMed
37.
Zurück zum Zitat Williams, DM, Magee, DM, Bonewald, LH, et al. 1990A role in vivo for tumor necrosis factor-α in host defence against Chlamydia trachomatisInfect Immun5815721576 Williams, DM, Magee, DM, Bonewald, LH,  et al. 1990A role in vivo for tumor necrosis factor-α in host defence against Chlamydia trachomatisInfect Immun5815721576
Metadaten
Titel
The Role of Pleural Fluid-Serum Gradient of Tumor Necrosis Factor-α Concentration in Discrimination Between Complicated and Uncomplicated Parapneumonic Effusion
verfasst von
M. Odeh
B. Makhoul
E. Sabo
I. Srugo
A. Oliven
Publikationsdatum
01.02.2005
Erschienen in
Lung / Ausgabe 1/2005
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-004-2519-y

Weitere Artikel der Ausgabe 1/2005

Lung 1/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.